Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) shares rose 2.7% during trading on Thursday . The stock traded as high as $3.10 and last traded at $3.06. Approximately 7,112 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 64,338 shares. The stock had previously closed at $2.98.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on the company. Guggenheim lowered their price target on Inventiva from $12.00 to $9.00 and set a "buy" rating for the company in a report on Friday, April 4th. HC Wainwright reiterated a "buy" rating and issued a $13.00 price target on shares of Inventiva in a report on Friday, March 28th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $10.40.
View Our Latest Stock Report on IVA
Inventiva Price Performance
The stock has a fifty day moving average price of $3.34 and a two-hundred day moving average price of $2.95.
Hedge Funds Weigh In On Inventiva
An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors and hedge funds own 19.06% of the company's stock.
About Inventiva
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Stories
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
